NO20022925D0 - EP4 reseptor selektive agonister for behandling av osteoporose - Google Patents

EP4 reseptor selektive agonister for behandling av osteoporose

Info

Publication number
NO20022925D0
NO20022925D0 NO20022925A NO20022925A NO20022925D0 NO 20022925 D0 NO20022925 D0 NO 20022925D0 NO 20022925 A NO20022925 A NO 20022925A NO 20022925 A NO20022925 A NO 20022925A NO 20022925 D0 NO20022925 D0 NO 20022925D0
Authority
NO
Norway
Prior art keywords
osteoporosis
treatment
selective agonists
receptor selective
receptor
Prior art date
Application number
NO20022925A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022925L (no
Inventor
Kimberly O'keefe Cameron
Huazhu Ke
Bruce Allen Lefker
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20022925L publication Critical patent/NO20022925L/no
Publication of NO20022925D0 publication Critical patent/NO20022925D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20022925A 1999-12-22 2002-06-18 EP4 reseptor selektive agonister for behandling av osteoporose NO20022925D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17135399P 1999-12-22 1999-12-22
PCT/IB2000/001711 WO2001046140A1 (en) 1999-12-22 2000-11-20 Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (2)

Publication Number Publication Date
NO20022925L NO20022925L (no) 2002-06-18
NO20022925D0 true NO20022925D0 (no) 2002-06-18

Family

ID=22623430

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022925A NO20022925D0 (no) 1999-12-22 2002-06-18 EP4 reseptor selektive agonister for behandling av osteoporose

Country Status (36)

Country Link
US (2) US6737437B2 (enExample)
EP (1) EP1110949B1 (enExample)
JP (1) JP2001181210A (enExample)
KR (1) KR100419681B1 (enExample)
CN (1) CN1413190A (enExample)
AP (2) AP2002002555A0 (enExample)
AT (1) ATE250575T1 (enExample)
AU (2) AU1293101A (enExample)
BG (1) BG106882A (enExample)
BR (1) BR0016560A (enExample)
CA (1) CA2329678A1 (enExample)
CO (1) CO5251453A1 (enExample)
CR (1) CR6678A (enExample)
CZ (1) CZ20022048A3 (enExample)
DE (1) DE60005471T2 (enExample)
DK (1) DK1110949T3 (enExample)
EA (1) EA005293B1 (enExample)
EE (1) EE200200355A (enExample)
ES (1) ES2204458T3 (enExample)
GE (1) GEP20043203B (enExample)
HR (1) HRP20020537A2 (enExample)
HU (1) HUP0005001A3 (enExample)
IL (1) IL140325A0 (enExample)
IS (1) IS6388A (enExample)
MA (1) MA26852A1 (enExample)
MX (1) MXPA02006322A (enExample)
NO (1) NO20022925D0 (enExample)
OA (1) OA12117A (enExample)
PE (1) PE20010953A1 (enExample)
PL (1) PL356662A1 (enExample)
PT (1) PT1110949E (enExample)
SK (1) SK8552002A3 (enExample)
TR (2) TR200201643T2 (enExample)
UA (1) UA72293C2 (enExample)
WO (1) WO2001046140A1 (enExample)
ZA (1) ZA200007694B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
SI1339678T1 (sl) 2000-11-27 2007-12-31 Pfizer Prod Inc Selektivni agonisti EP4 receptorja pri zdravljenju osteoporoze
AU2002328855B2 (en) * 2001-07-16 2005-11-24 F. Hoffmann-La Roche Ag Prostaglandin Analogues As EP4 Receptor Agonists
AU2002328338C1 (en) * 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
KR100826866B1 (ko) 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제
EP1452178A1 (en) * 2001-11-12 2004-09-01 Ono Pharmaceutical Co., Ltd. Persistent filmy preparation for topical administration containing prostaglandin derivative
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
CA2466751A1 (en) * 2001-12-03 2003-06-12 Merck And Co., Inc. Ep4 receptor agonist, compositions and methods thereof
US7335680B2 (en) 2001-12-20 2008-02-26 Laboratoires Serono Sa Pyrrolidine derivatives as prostaglandin modulators
JP4547912B2 (ja) 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103604A2 (en) * 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactams as prostaglandin agonists and use thereof
EP1513589B1 (en) 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
WO2004032965A1 (ja) 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
EP1581503A4 (en) 2002-11-08 2007-07-25 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
MXPA05007341A (es) 2003-01-10 2005-09-30 Hoffmann La Roche Derivados de 2-piperidona como agonistas de prostaglandina.
EP1586564B1 (en) * 2003-01-21 2012-11-28 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medicinal uses thereof
WO2004078103A2 (en) 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US6734201B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
WO2005012232A2 (en) * 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
AU2004271978B2 (en) 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1663987B1 (en) 2003-09-04 2009-03-18 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
US7563816B2 (en) 2004-07-20 2009-07-21 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2006061366A1 (en) 2004-12-06 2006-06-15 Laboratoires Serono S.A. Pyrrolidin-2-one derivatives for use as dp1 receptor agonists
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
EP1878429B1 (en) 2005-04-28 2011-08-03 Ono Pharmaceutical Co., Ltd. Trenadermal absorption preparation
KR100686186B1 (ko) * 2005-06-13 2007-02-26 영진종합건설 주식회사 교량용 배수 구조물
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
EP2085088A4 (en) 2006-10-26 2012-08-29 Ono Pharmaceutical Co ADHESIVE PREPARATION
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
EP2220057A4 (en) 2007-11-14 2011-10-12 Cayman Chem Co PROSTAGLANDIN E1 AND E2 ANALOGUES FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
BR112014002377A2 (pt) 2011-08-02 2017-02-21 Ono Pharmaceutical Co agente intensificador da função diastólica do ventrículo esquerdo
CA2879506C (en) 2012-07-19 2020-10-27 Cayman Chemical Company, Inc. Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
BR112015023080A2 (pt) 2013-03-15 2017-07-18 Cayman Chemical Co Inc composto, composição farmacêutica, e, método para tratamento de doenças
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
AU2014290512A1 (en) 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
CA2988523A1 (en) 2015-06-12 2016-12-15 Simon Fraser University Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR897566A (fr) 1942-08-28 1945-03-26 Bopp & Reuther Gmbh Machine à rotors
US3528961A (en) 1966-08-16 1970-09-15 Allied Chem Monoazo dyes from e-caprolactam
US3780095A (en) 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
SE7414770L (enExample) 1973-12-13 1975-06-16 Merck & Co Inc
DK366475A (da) 1974-08-30 1976-03-01 Merck & Co Inc Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US4055596A (en) 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
DE2528664A1 (de) * 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4243678A (en) 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de) 1980-11-11 1982-06-24 A. Nattermann & Cie GmbH, 5000 Köln N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0068968B1 (fr) 1981-06-16 1985-09-18 Choay S.A. Nouveaux médicaments contenant à titre de substance active des composés du type arylbenzènesulfonamide et leurs procédés de préparation
AU6427596A (en) * 1992-04-14 1996-10-31 Alfred Maximillian Stessl A boat hull
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
IL130333A0 (en) * 1996-12-20 2000-06-01 Pfizer Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
JP2002527400A (ja) * 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨形成刺激方法
WO2000021532A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption

Also Published As

Publication number Publication date
AU1293101A (en) 2001-07-03
DK1110949T3 (da) 2003-11-24
WO2001046140A1 (en) 2001-06-28
CA2329678A1 (en) 2001-06-22
HUP0005001A3 (en) 2002-01-28
AU7239300A (en) 2001-06-28
US20010047105A1 (en) 2001-11-29
SK8552002A3 (en) 2003-09-11
PL356662A1 (en) 2004-06-28
CR6678A (es) 2004-01-14
NO20022925L (no) 2002-06-18
HRP20020537A2 (en) 2004-12-31
US6737437B2 (en) 2004-05-18
US6642266B2 (en) 2003-11-04
CZ20022048A3 (cs) 2004-03-17
AU763983B2 (en) 2003-08-07
DE60005471D1 (de) 2003-10-30
DE60005471T2 (de) 2004-04-22
EA005293B1 (ru) 2004-12-30
OA12117A (en) 2006-05-04
CO5251453A1 (es) 2003-02-28
AP2001002357A0 (en) 2001-12-31
BR0016560A (pt) 2002-09-10
EE200200355A (et) 2003-10-15
HUP0005001A2 (hu) 2001-12-28
MXPA02006322A (es) 2002-12-13
EA200200505A1 (ru) 2002-12-26
AP2002002555A0 (en) 2002-06-30
BG106882A (en) 2003-02-28
US20020040149A1 (en) 2002-04-04
PT1110949E (pt) 2003-12-31
UA72293C2 (en) 2005-02-15
KR20010067415A (ko) 2001-07-12
ES2204458T3 (es) 2004-05-01
GEP20043203B (en) 2004-03-25
CN1413190A (zh) 2003-04-23
ZA200007694B (en) 2002-06-20
HU0005001D0 (enExample) 2001-02-28
TR200301841T4 (tr) 2004-01-21
TR200201643T2 (tr) 2002-11-21
KR100419681B1 (ko) 2004-02-21
PE20010953A1 (es) 2001-09-25
JP2001181210A (ja) 2001-07-03
IS6388A (is) 2002-05-17
ATE250575T1 (de) 2003-10-15
MA26852A1 (fr) 2004-12-20
EP1110949A1 (en) 2001-06-27
IL140325A0 (en) 2002-02-10
EP1110949B1 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
NO20022925D0 (no) EP4 reseptor selektive agonister for behandling av osteoporose
NO20032360L (no) EP4 reseptor selektive agonister for behandling av osteoporose
NO20022105D0 (no) Positive modulatorer av nikotinreseptoragonister
NO20016246D0 (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
PT1189916E (pt) N-pirazole agonistas do receptor a2a
NO20014379L (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
NO20013380D0 (no) 2-aminobenzoksazinonderivater for behandling av fedme
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
DE60028368D1 (de) Agonisten des peroxisom aktivator-responsiven rezeptors
NO20022009D0 (no) Positive modulatorer av nikotiniske reseptoragonister
EP1121939A3 (en) Treatment of osteoporosis with EP2/EP4 receptor selective agonists
NO20022142L (no) Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
FI5227U1 (fi) Laitteisto laastin jakelemiseksi
DK1200402T3 (da) Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande
TW376691U (en) Structure of combination device for the flashing ornaments

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application